Psoriasis Biotech Stocks Soar with New Data, Hitting Record Highs

On the Nasdaq, Oruka Therapeutics (ORKA) closed at $77.50, up 12.27%, roughly ₩109,000 per share. Its market capitalization climbed to about $3.84 billion (around ₩5.4 trillion), gaining approximately $540 million (roughly ₩750 billion) in a single day.

The stock surge was driven by interim data from the 16-week readout of the EVERLAST-A Phase 2a trial of its lead candidate ORKA-001, which showed that 63.5% of moderate-to-severe plaque psoriasis patients achieved complete skin clearance, combined with Stifel raising its price target from $72 to $150 while maintaining a buy rating. (orukatx.com)

Oruka Therapeutics is a clinical-stage biotech developing extended half-life monoclonal antibodies for chronic skin diseases, including psoriasis. The company aims to replace existing biologics with once-to-three-times-a-year dosing, led by ORKA-001 targeting IL-23p19 and ORKA-002 targeting IL-17A/F. (nasdaq.com)